Skip to content
Partnership for Safe Medicines
  • News
    • Diabetes & Weight-loss Injectables
    • Fake HIV Medications
    • PBMs
    • Botox / Botulism warning
    • Illegal Pill Presses
    • Fake Adderall
    • Poisonous cough syrup
    • Social Media & Fake Pills
    • Counterfeit Pill Crisis
  • Patients
    • Learn about Counterfeits and to Save Money Safely
    • The Drug Importation Debate
    • Drug Counterfeiters Get Light Sentences
    • Real Victims of Counterfeit Drugs
    • Talk to Your Family
    • HIV/HEPC Patients
    • Mexican Pharmacies
  • Professionals
    • Pharmacists
    • Doctors
    • Law Enforcement
    • Educators
    • Prosecution Document Library
    • Research On Drug Safety
  • Policy
    • Publications
    • Drug Importation
    • PBM under-reimbursement
    • Illegal Pill Presses
    • Affordability Boards (PDABs)
    • Alternative funding programs (AFPs)
    • Pharmacy-to-pharmacy marketplaces
    • FOIA-ed Materials
    • Events, briefings, and op-eds
  • About Us
    • Join Our Mailing List
    • Members
    • PSM Leadership
    • Press Releases
    • Contact Us
Document Tags: Case 2:23-cv-02369-TLP-atc, Complaint, compounding, GLP-1 lawsuit, Novo Nordisk, Pro Health Investments, semaglutide, Tennessee
Return to list

Return to the list of compounded GLP-1 lawsuits

 

United States District Court
Western District of Tennessee

Novo Nordisk v Pro Health Investments, LLC

Complaint

June 20, 2023

Read the document.

NN-ProHealth-TN-suit-6-2023
© 2003-2023 Partnership for Safe Medicines
Click here to contact us.
Facebook Twitter Linkedin Youtube Instagram Email
Scroll To Top